• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-08-12

  FITC-Concanavalin A (ConA) Conjugate, SKU K4413, is a fluorescent lectin probe for visualizing accessible α-D-glucose and α-D-mannose moieties on glycoproteins and glycolipids. It is suited to cell surface carbohydrate detection, immunofluorescence staining, and flow cytometry, but not to identifying a specific glycoprotein or analyzing non-carbohydrate targets.

• Palomid 529 (P529) in Assay Design

  2026-08-12

  This scenario-based guide shows how Palomid 529 (P529), SKU A8618, can be incorporated into viability, proliferation, angiogenesis, and pathway-dependence experiments. It emphasizes solvent control, dose interpretation, storage, and vendor-selection criteria grounded in the product dossier and recent PI3K-AKT research.

• JZL184 and the CB1–GLT-1 Axis in TBI

  2026-08-11

  JZL184 offers a precise way to interrogate how MAGL-dependent 2-AG turnover shapes CB1 signaling, astrocytic GLT-1 expression, excitotoxicity, and cognitive outcomes after traumatic brain injury. This thought-leadership perspective translates recent mechanistic findings into an experimental strategy while clarifying what JZL184 can—and cannot—establish in translational neurobiology.

• BX795: PDK1 Inhibitor for Kinase and Immune Studies

  2026-08-11

  BX795 is an ATP-competitive PDK1 inhibitor with additional TBK1 and IKKε activity. Its profile supports mechanistic studies of PI3K/Akt/mTOR signaling, cancer cell growth inhibition, and innate immune response modulation, but cellular effects should not be assigned to PDK1 alone.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-08-10

  This preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in rats by integrating nasal inflammation, Th1/Th2-associated signaling, intestinal microbiota, and serum short-chain fatty acids. Its main contribution is a multilevel association between treatment-related symptom improvement, microbiome shifts, increased SCFAs, and reduced allergic and nasal molecular markers, while its preclinical design limits causal and clinical interpretation.

• BODIPY 581/591 C11 in Ferroptosis Assays

  2026-08-09

  BODIPY 581/591 C11 is a ratiometric fluorescent probe for resolving membrane lipid peroxidation in endothelial ferroptosis studies. This article connects its spectral biology to the SOCE/O-GlcNAcylation findings reported in diabetic osteoporosis and explains how to avoid overinterpreting oxidative stress signals.

• Hexetidine (NSC-17764) Assay Guide

  2026-08-08

  A scenario-driven laboratory guide to using Hexetidine (NSC-17764), SKU BA1327, in antimicrobial, biofilm, and cell-compatibility workflows. It explains concentration selection, solvent controls, MIC interpretation, assay limitations, and practical vendor-selection criteria using product data and published evidence.

• Mapping SLC2A5 in CNS Lymphoma Tissue

  2026-08-07

  Single-cell evidence positions SLC2A5-mediated fructose metabolism as a potential vulnerability in primary CNS lymphoma. This thought-leadership guide translates that finding into practical, mechanism-aware tissue assay strategies using a Primary Antibody Dilution Buffer while distinguishing research evidence from workflow recommendations.

• Sulfaphenazole: Precision CYP2C9 Inhibitor for Vascular Rese

  2026-08-07

  Sulfaphenazole stands out as a selective CYP2C9 inhibitor, enabling robust workflows in vascular endothelial function and drug metabolism studies. Its well-characterized inhibition profile, low cytotoxicity, and translational impact are showcased by recent data-driven applications in diabetic vascular dysfunction and tissue injury models.

• PPP1R3G/PP1γ-Mediated RIPK1 Dephosphorylation Drives Cell De

  2026-08-06

  This study uncovers how PPP1R3G recruits PP1γ to dephosphorylate and activate RIPK1, thereby promoting apoptosis and necroptosis. The findings clarify a key regulatory checkpoint in inflammation and cell death, with implications for the targeted modulation of the NF-κB pathway in disease models.

• NADH in Mitochondrial Electron Transport Chain Research

  2026-08-06

  NADH (reduced nicotinamide adenine dinucleotide) empowers advanced mitochondrial electron transport chain research, disease modeling, and next-generation photocatalytic cancer therapy. This guide translates recent breakthroughs and reference-backed protocols into actionable workflows, troubleshooting insights, and practical innovations for high-fidelity metabolic assays.

• SlSLAH1-Mediated Malate Exudation Confers Aluminium Toleranc

  2026-08-05

  This study defines a molecular pathway in tomato where the anion channel SlSLAH1, regulated by the SlSTOP1-SlSZP1 transcriptional complex, drives malate exudation to mitigate aluminium toxicity. The findings clarify key regulatory components underlying aluminium tolerance and open new avenues for crop improvement.

• Partial Amyloid β Reduction Preserves Synaptic Function in A

  2026-08-05

  Satir et al. (2020) demonstrate that moderate inhibition of amyloid β production via β-secretase inhibitors does not impair synaptic transmission in primary neuronal cultures. This finding challenges previous concerns about negative cognitive effects from such interventions and informs future directions for Alzheimer’s disease therapeutics design.

• BX795 (SKU A8222): Precision PDK1 Inhibition for Cell Assays

  2026-08-04

  This article provides scenario-driven guidance for using BX795 (SKU A8222) as a selective PDK1 inhibitor in cell viability, proliferation, and cytotoxicity assays. It addresses real-world laboratory challenges, offering evidence-backed protocol recommendations and vendor selection insights, to help researchers achieve reproducible, quantitative results in cancer and immune signaling studies.

• Chenodeoxycholic Acid: FXR-KLF11 Pathway in Translational Re

  2026-08-04

  This thought-leadership article explores the mechanistic and translational significance of Chenodeoxycholic Acid (CDCA) as an FXR agonist, focusing on the FXR-KLF11-JAK2/STAT3 axis in contrast-induced acute kidney injury (CI-AKI). Integrating recent preclinical breakthroughs, we provide strategic guidance for researchers leveraging CDCA in nuclear receptor signaling, cholesterol metabolism, and kidney injury models, with protocol insights and a forward-looking perspective.

8490 records 2/566 page Previous Next 12345 下5页 Last page